- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03245190
Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma
Efficacy and Safety of Chiauranib in Advanced Hepatocellular Carcinoma: a Single-arm, Open-label, Multi-center, Exploratory Phase Ib Study
Study Overview
Detailed Description
Chiauranib is a novel orally active multi-target inhibitor that simultaneously inhibits the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRa and c-Kit), mitosis-related kinase Aurora B and chronic inflammation related kinase CSF-1R in a high potency manner with the IC50 at a single-digit nanomolar range. In particular, Chiauranib showed very high selectivity in the kinase inhibition profile with little activity on off-target non-receptor kinases, proteins, GPCR and ion channels, indicative of a better drug safety profile in terms of clinical relevance.
Because of its broad preclinical anti-tumor efficacy and the potential to improve conventional TKI kinase inhibitor therapy in various cancer indications, Chiauranib has now entered phase Ib clinical trials.
This clinical trial is studying the efficacy and safety of chiauranib works in treating patients with advanced hepatocellular carcinoma, in the meantime, exploring the latent biomarkers accompany with chiauranib, as well as the relevancy of which and clinical benefit.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Zhongshan Hospital of Fudan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, age ≥ 18 years and ≤70 years.
- Histological or cytological confirmation of HCC (hepatocellular carcinoma) or non-invasive diagnosis of HCC as per American Association for the Study of Liver Diseases criteria in patients with a confirmed diagnosis of cirrhosis.
- Barcelona Clinic Liver Cancer stage Category B or C that cannot benefit from treatments of locoregional therapy, or provided that progression has been documented after these therapies.
- Patients should have failed or been intolerant of at least one prior systemic therapy regimen which could include systemic chemotherapy (such as oxaliplatin, arsenious acid) and/or sorafenib.
- At least one uni-dimensional measurable lesion according to RECIST (RECIST version 1.1), and modified RECIST for HCC (mRECIST):a. HCC lesions should have at least one accurate repeated dimension as 1 cm or more ); b. extrahepatic lesions: a lymph node must be 1.5 cm or more in short axis, and Non-lymph node lesions must be at least 1 cm in longest diameter. Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, may be considered measurable if there has been demonstrated progression in the lesion.
- Liver function status Child-Pugh Classification with score ≤ 7 points. Child Pugh status should be calculated based on clinical findings and laboratory results during the screening period.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Laboratory criteria are as follows (laboratory results within 7 days prior to first dose, and without receiving any supportive treatment for the following parameters within 2 weeks from the last dose prior to study entry):
- Complete blood count: white blood cell count ≥ 3.0×109/L; absolute neutrophil count (ANC) ≥1.5×109/L ;hemoglobin (Hb) ≥85g/L ; platelets >=60×109/L
- Biochemistry test: total bilirubin≦1.5×ULN; alanine aminotransferase(ALT) ,aspartate aminotransferase(AST)≦5×ULN ; plasma albumin≥ 28 g/L; serum creatinine(cr)≦1.5×ULN; serum amylase≦1.5×ULN;
- Coagulation test: International Normalized Ratio (INR) < 1.5; activated partial thromboplastin time (APTT) < 1.5×ULN
- Thyroid function test: thyroid stimulating hormone (TSH) < 10mIU/L;
- Life expectancy of at least 12 weeks.
- All patients must have given signed, informed consent prior to registration on study.
Exclusion Criteria:
- Any target treatment like sorafenib within 2 weeks prior to first dose of study drug; With the exception of target treatment, any anti-cancer systemic treatment (including chemotherapy, immunotherapy, radiotherapy, and anti-cancer Chinese traditional medicine, et al) or locoregional therapy (including but not limited to surgery, radiofrequency ablation or transarterial chemoembolization ) within 4 weeks prior to first dose of study drug; any supportive treatment for haematology (including transfusion, blood products, or drugs that stimulate blood cells growth like G-CSF, et al) within 2 weeks prior to first dose of study drug.
- Known Cholangiocarcinoma or Fibrolamellar Hepatocellular Carcinoma; Known history of, or ongoing second primary cancer, except: adequately treated basal cell or squamous cell skin cancer, curatively treated in-situ cancer of the cervix, unless received curative treatment and with documented evidence of no recurrence during the past five years;
- Known metastatic brain or meningeal tumors
Patients with uncontrolled or significant cardiovascular disease, including:
- Grade II or higher Congestive heart failure, unstable angina pectoris, myocardial infarction (NYHA Classification) within 6 months prior to study entry; or arrhythmia requiring treatment, or Left Ventricular Ejection Fraction (LVEF) < 50% during screening stage.
- Primary cardiomyopathy (dilated cardiomyopathy, hypertrophic cardiomyocyte, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, et,al).
- History of significant QT interval prolongation, or Corrected QT Interval QTc≥450ms(male), QTc≥470ms(female)at screening.
- Symptomatic coronary heart disease requiring treatment.
- Uncontrolled hypertension (> 140/90 mmHg) with single medication.
- History of active bleeding within 6 months or esophageal varices bleeding led by portal hypertension within 2 months prior to screening ; or patients receiving anticoagulation therapy; or patients with evidence of GI bleeding potential.
- Uncontrolled ascites or pleural effusion (defined as not easily controlled with diuretic or paracentesis treatment).
- History of transjugular intrahepatic portosystemic shunts (TIPSS).
- History of abdominal fistula, gastrointestinal perforation or abdominal abscess within 28 days prior to screening.
- History of deep vein thrombosis or pulmonary embolism.
- History of interstitial lung disease(ILD), or with ongoing signs and symptoms at the time of screening.
- History of hypothyroidism; or patients receiving substitutional treatment with thyroid hormone.
- With any ongoing toxicities (>CTCAE grade 1) caused by previous cancer therapy.
- Patients with factors that could affect oral medication (such as dysphagia, chronic diarrhea, intestinal obstruction etc), or undergone gastrectomy.
- History of liver transplantation, or patients in preparation of liver transplantation.
- 6 weeks or less from the last major surgery that involved general anaesthesia, or 2 weeks or less from the last minor surgery prior to screening (excluding placement of vascular access ) .
- Proteinuria positive(≥1g/24h).
- Patients with active or unable to control infections including human immunodeficiency virus (HIV), or other serious infectious diseases.
- Patients with untreated active hepatitis B virus (HBV) (HBsAg positive and HBV DNA ≥ 2000 IU/mL) . But patients with controlled(treated) HBV fulfilling the following criteria can be eligible for the study: HBV DNA< 2000 IU/mL , or patients on anti-HBV suppression with HBV DNA< 2000 IU/mL before study enrollment.
- Patients with untreated active hepatitis C virus.
- Any mental or cognitive disorder, that would impair the ability to understand the informed consent document, or limit compliance with study requirements/treatment.
- Any previous treatment with aurora kinase inhibitors.
- Candidates with drug abuse.
- Women of childbearing potential not willing to use and utilize an adequate method of contraception (such as intrauterine device, contraceptive and condom) throughout treatment and for at least 12 weeks after the last dose; pregnant or breastfeeding women; the result of urine pregnancy test was positive at screening; Man participants not willing to use and utilize an adequate method of contraception throughout treatment.
- Any other condition which is inappropriate for the study according to investigators' judgment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Chiauranib
Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
|
50mg, orally once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
16 weeks progression-free rate (16W-PFR)
Time Frame: Up to a minimum 16 weeks after the last participant's first dose, or progression, or died, whichever came first
|
Up to a minimum 16 weeks after the last participant's first dose, or progression, or died, whichever came first
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response (DOR)
Time Frame: Approximately 24 months
|
Approximately 24 months
|
|
Overall survival (OS)
Time Frame: Approximately 24 months
|
Approximately 24 months
|
|
Rate of Treatment-Related Adverse Events in Study Participants
Time Frame: Up to a minimum 20 weeks after the last participant's first dose, or progression, or 75% subjects died, whichever came first, assessed up to 24 months
|
Safety evaluation as measured by adverse events (AE), vital signs,electrocardiograph(ECG) and abnormal laboratory results according to CTCAE V4.03
|
Up to a minimum 20 weeks after the last participant's first dose, or progression, or 75% subjects died, whichever came first, assessed up to 24 months
|
Time to progression(TTP)
Time Frame: Approximately 24 months
|
Approximately 24 months
|
|
Objective response rate (ORR)
Time Frame: Approximately 24 months
|
ORR is defined as the percentage of participants whose best overall response is either complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and modified RECIST for HCC (mRECIST), respectively.
|
Approximately 24 months
|
Disease-control rate (DCR)
Time Frame: Approximately 24 months
|
Approximately 24 months
|
|
Progression-free survival (PFS)
Time Frame: Approximately 24 months
|
Approximately 24 months
|
|
6 months progression-free rate
Time Frame: At 6 months
|
At 6 months
|
|
6 months overall survival rate
Time Frame: At 6 months
|
At 6 months
|
|
12 months overall survival rate
Time Frame: At 12 months
|
At 12 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Median score of immunohistochemical expressed by Aurora B、CSF-1R and Myc protein.
Time Frame: Assessed up to 24 months
|
Assessed up to 24 months
|
Screening characteristics of ctDNA measurement (single gene analysis).
Time Frame: Assessed up to 24 months
|
Assessed up to 24 months
|
Screening characteristics of ctDNA measurement (multi-gene analysis).
Time Frame: Assessed up to 24 months
|
Assessed up to 24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Chiauranib
Other Study ID Numbers
- CAR104
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
Clinical Trials on Chiauranib
-
AkesoChipscreen Biosciences, Ltd.RecruitingSCLC,Extensive StageAustralia, China
-
Chipscreen Biosciences, Ltd.RecruitingSmall Cell Lung CancerChina
-
Chipscreen Biosciences, Ltd.Terminated
-
Chipscreen Biosciences, Ltd.RecruitingOvarian Cancer | Relapsed or Refractory | Chiauranib | PaclitaxelChina
-
Chipscreen Biosciences, Ltd.Completed
-
Chipscreen Biosciences, Ltd.Recruiting
-
Chipscreen Biosciences, Ltd.Recruiting
-
Chipscreen Biosciences, Ltd.Completed
-
Chipscreen Biosciences, Ltd.CompletedSmall Cell Lung CancerChina
-
Chipscreen Biosciences, Ltd.H & J CRO International, Inc.Completed